Employers do not have to choose between covering GLP-1 medications on the health plan and ignoring employee demand. A third route exists: give employees clinical access to GLP-1 and metabolic care as a voluntary, employee-paid benefit outside the plan, and invest the employer budget in the prevention that reduces demand over time.

GLP-1 spending is the symptom, the disease is a workforce whose daily environment and habits work against basic metabolic health. Employers who treat the drug as the strategy will keep paying more every year for a problem that keeps growing.

What made the GLP-1 boom almost inevitable?

The answer starts long before the prescription. Obesity, diabetes, prediabetes, physical inactivity, and poor nutrition already affect a large share of the U.S. population. GLP-1 demand did not appear in a vacuum, it grew on top of a metabolic-health problem that had been building for years.

Among U.S. adults 18 and older:

• 40.3% live with obesity (CDC)
• 14.7% live with diabetes (CDC National Diabetes Statistics Report)
• 38% live with prediabetes (CDC National Diabetes Statistics Report)
• 25.3% report no physical activity outside of work (CDC)
• 12.3% meet the recommended fruit intake (CDC)
• 10% meet the recommended vegetable intake (CDC)

GLP-1s became a corporate benefits issue because demand grew on top of a much larger metabolic-health problem. More than 40% of U.S. adults live with obesity, 42.6% have prediabetes, and one in four report no physical activity outside of work. The prescription boom did not create those conditions, it exposed them. CDC.

Employers who only budget for the medication are treating a systemic problem with a single-line fix. The roof is still leaking and the bucket just got more expensive.

GLP-1s work but they're not designed to fix the soil

For employees who meet clinical criteria, GLP-1 medications are an established treatment, and access to them matters. The problem starts when drug access becomes the entire strategy instead of one part of it.

The research on prevention is direct about what moves the needle:

• Movement and lifestyle change: In the landmark Diabetes Prevention Program, participants in an intensive lifestyle intervention reduced their risk of developing Type 2 diabetes by 58% over about three years, compared with placebo. Participants taking metformin reduced their risk by 31%. The lifestyle program targeted at least 150 minutes of physical activity per week along with modest weight loss.
• Sleep: Sleep restriction has measurable effects on metabolic health. A meta-analysis of 41 randomized controlled trials found that sleep restriction increased subjective hunger, was associated with about 253 additional calories consumed per day, and reduced insulin sensitivity.
• Physical inactivity: 25.3% of U.S. adults reported doing no physical activity outside of work in CDC data covering 2017–2020. That matters because regular physical activity is one of the modifiable behaviors used in evidence-based diabetes prevention programs.

Betterspan, Betterfly's model, treats six daily habits as the soil everything else grows from: exercise, nutrition, sleep, mind, community and environment.

An employer who funds the prescription without addressing these conditions is paying at the treatment stage while leaving earlier intervention largely untouched.

Why does GLP-1 coverage become an employer problem?

The traditional health plan hands employees an insurance card for when something goes wrong. That model made sense before chronic metabolic disease became the dominant cost driver, but it doesn't anymore.

Employers are already paying for metabolic health, whether they approach it proactively or wait for it to appear in the pharmacy budget.

Mercer expects employer-sponsored health benefit costs to exceed $18,500 per employee in 2026, up 6.7% from 2025. Prescription drug spending among large employers rose 9.4% in 2025, with growing GLP-1 utilization among the drivers.

The GLP-1 numbers make the pressure even clearer. Among employers with 5,000 or more workers that cover the drugs for weight loss, 59% said utilization was higher than expected and 66% said the coverage had a significant impact on prescription drug spending, according to KFF's 2025 Employer Health Benefits Survey.

Employers cannot control every determinant of an employee's health. They do control part of the environment employees spend their working lives inside. Employers can encourage movement, make preventive benefits easier to find, and give employees reasons to engage with their health before a diagnosis.

A workplace that normalizes long sedentary stretches while giving employees little reason to engage with preventive health is leaving one of its few controllable levers unused.

Sources:

1. CDC — Diabetes Surveillance and Public Health Data (https://www.cdc.gov/diabetes/php/data-research/index.html (https://www.cdc.gov/diabetes/php/data-research/index.html))

2. CDC — Diabetes Surveillance and Public Health Data (https://www.cdc.gov/diabetes/php/data-research/index.html (https://www.cdc.gov/diabetes/php/data-research/index.html))

3. CDC — Physical Inactivity Prevalence and Geographic Trends (https://www.cdc.gov/physical-activity/php/data/inactivity-maps.html (https://www.cdc.gov/physical-activity/php/data/inactivity-maps.html))

4. CDC — Physical Inactivity and Health Risks (https://www.cdc.gov/mmwr/volumes/71/wr/mm7101a1.htm (https://www.cdc.gov/mmwr/volumes/71/wr/mm7101a1.htm))

5. NIDDK — Diabetes Prevention Program and Lifestyle Intervention (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/diabetes-prevention-program-dpp (https://www.niddk.nih.gov/about-niddk/research-areas/diabetes/diabetes-prevention-program-dpp))

6. PubMed — Research on Diabetes Prevention and Health Outcomes (https://pubmed.ncbi.nlm.nih.gov/30870662/ (https://pubmed.ncbi.nlm.nih.gov/30870662/))

7. CDC — Physical Inactivity Prevalence and Geographic Trends (https://www.cdc.gov/physical-activity/php/data/inactivity-maps.html (https://www.cdc.gov/physical-activity/php/data/inactivity-maps.html))

8. Mercer — Rising Employer Health Insurance Costs and Affordability Challenges (https://www.mercer.com/en-us/about/newsroom/employers-and-workers-face-affordability-crunch-as-health-insurnace-cost-is-expected-to-exceed-18500-per-employee-in-2026/ (https://www.mercer.com/en-us/about/newsroom/employers-and-workers-face-affordability-crunch-as-health-insurnace-cost-is-expected-to-exceed-18500-per-employee-in-2026/))

9. KFF — Employer-Sponsored Health Insurance Costs and Coverage Trends (https://www.kff.org/health-costs/2025-employer-health-benefits-survey/ (https://www.kff.org/health-costs/2025-employer-health-benefits-survey/))

10. FDA — Treatment to Reduce Cardiovascular Risk in Adults With Obesity (https://www.fda.gov/news-events/press-announcements/la-fda-aprueba-el-primer-tratamiento-para-reducir-el-riesgo-de-problemas-graves-del-corazon (https://www.fda.gov/news-events/press-announcements/la-fda-aprueba-el-primer-tratamiento-para-reducir-el-riesgo-de-problemas-graves-del-corazon))

11. FDA — Treatment to Reduce Cardiovascular Risk in Adults With Obesity (https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or (https://www.fda.gov/news-events/press-announcements/fda-approves-first-treatment-reduce-risk-serious-heart-problems-specifically-adults-obesity-or))